oestrogens to the cells. While the supply of oestrogens can be reduced by castration in premenopausal women, such treatment has little impact on post-menopausal oestrogens because ovarian secretion of oestrogens ceases at the menopause (Dowsett et al., 1987; Vermeulen et al., 1976) . The major pathway of oestrogen production in post-menopausal women is by the conversion of circulating androstenedione to oestrone by peripheral tissue (Grodin et al., 1973) . In this group about 70% of circulating androstenedione is of adrenal origin, the rest being thought to be secreted by the ovaries (Vermeulen., 1976) . Adrenalectomy and hypophysectomy were introduced nearly 40 years ago as possible treatments of advanced breast cancer in post-menopausal patients (Huggins & Dao, 1953; Luft et al., 1952) , and although the mechanisms of action at that time were not clear, later studies confirmed that these ablative procedures caused tumour regression in about 35% of such patients (Fracchia et al., 1971) . Due to the morbidity and mortality of such procedures the possibility of achieving similar effects by drug treatment has been investigated. Treatment with glucocorticoids to achieve a medical suppression of adrenal function was introduced 30 years ago (Kofman et al., 1958) , but it soon become clear that the response rates were lower than those seen following surgical adrenalectomy (Dao et al., 1961) .
In 1967 aminoglutethimide, an unsuccessful antiepileptic drug which had been shown to possess adrenal toxicity, was introduced in an attempt to provoke a more effective 'medical adrenalectomy' in breast cancer patients (Cash et al., 1967) . However, while clinical results were promising (Santen et al., 1974) , it soon became clear that this drug did not act by suppressing adrenal steroid synthesis. The finding that plasma androstenedione levels were preserved or even increased despite a substantial fall in plasma oestrone, suggested that aminoglutethimide might inhibit the production of oestrone from androstenedione (Samojlik et al., 1977) . This possibility was supported by the earlier observations of Thompson & Siiteri (1974) in vitro, and in 1978 Santen and co-workers confirmed that aminoglutethimide caused a 95-98% inhibition of aromatisation in post-menopausal patients with breast cancer (Santen et al., 1978) . This led to the introduction of the term 'aromatase inhibition' as a mechanism of endocrine treatment for breast cancer.
Randomised studies have confirmed that aminoglutethimide causes response rates similar to adrenalectomy (Newsome et al., 1977; Santen et al., 1981) as well as to tamoxifen (Harvey et al., 1982; Smith et al., 1981) . While aminoglutethimide treatment is favourable in comparison to surgical ablative procedures in terms of morbidity and mortality, a certain number of side-effects such as skin rash, ataxia and drowsiness make this drug less suited to first-line treatment than tamoxifen (L0nning & Kvinnsland, 1988) . However, since tamoxifen is being used increasingly as adjuvant therapy, there is a need for a new first-line drug for those patients who progress to advanced disease. Accordingly, considerable effort is being spent on developing more specific aromatase inhibitors, which will hopefully possess fewer side effects.
One further disadvantage with aminoglutethimide is its action on enzyme systems other than the aromatase. In the adrenals, it inhibits 20,22-desmolase, ll#-hydroxylase, 18-hydroxylase and possibly 21-hydroxylase (Cohen 1968 ; Dexter et al., J967; Kahnt & Neher, 1966; Sheppard et al., 1966) . Although a compensatory increase in ACTH secretion (Fishman et al., 1967) causes a sustained output of most steroids (Harris et al., 1983; Vermeulen et al., 1983) , the adrenal glucocorticoid response may be inadequate in certain circumstances, and glucocorticoid, and sometimes mineralocorticoid, replacement therapy are therefore recommended. Androstenedione (the one hormone for which a depression might be beneficial) is sustained or elevated unless the patient is given concommitant glucocorticoid therapy (Samojlik & Santen, 1978) . Thus, although aminoglutethimide was at one time thought to achieve a medical adrenalectomy' the overall result of the adrenal effects of aminoglutethimide is detrimental rather than advantageous to the aim of oestrogen depression. The lack of such adrenal effects is an important consideration in the development of new inhibitors.
In the liver, aminoglutethimide acts as an inducer of certain mixed function oxidases, causing an increased metabolism of various substances including some drugs (L0nning et al., 1984) . Recently, the metabolic clearance rate of oestrone sulphate was also found to be increased by aminoglutethimide (L0nning et al., 1987) . This effect could be beneficial because oestrone sulphate may be an important source of oestrogen for breast tumours, by metabolism to oestradiol within the tumour (Santner et al., 1984) . This increased metabolism may be of similar quantitative importance to the inhibition of production in reducing the plasma levels of oestrone sulphate (L0nning et al., 1989) . Thus, it seems that aminoglutethimide may act by a dual mechanism of action: (1) aromatase inhibition and (2) suppressing the plasma levels of oestrone sulphate by increasing its metabolism.
Although generally used in combination with hydrocortisone, the work of Stuart-Harris et al. (1984) was valuable in demonstrating that aminoglutethimide was clinically active in the absence of adrenal suppression. The question of the optimum dose of aminoglutethimide to use remains open. Results from the daily use of 250mg of aminoglutethimide alone seem to be inferior to those from using the conventional (l000mgday-1) plus hydrocortisone (Stuart- Harris et al., 1984; Murray & Pitt, 1985) . Clinical and endocrine evidence that 250mg daily with glucocorticoids is sufficient (Downsett et al., 1985; Harris et al., 1986 ) require confirmation in randomised trials. One randomised trial comparing aminoglutethimide 500mgday-1 to 1000mgday-1 revealed no significant difference in response rate (Boneterre et al., 1985) .
Testololactone is a weak androgen which was also found to be an aromatase inhibitor (Barone et al., 1979) after its introduction as an endocrine treatment of breast cancer nearly 30 years ago (Segaloff et al., 1960) . While in vitro investigations have confirmed that this drug is a weaker aromatase inhibitor than aminoglutethimide (Santen et al., 1982a) , it causes a 90% inhibition of aromatisation in vivo (Barone et al., 1979) . This contrasts with a low clinical response rate of only 10-14% in post-menopausal breast cancer patients (Volk et al., 1974) .
Although many investigators believe aromatisation of androstenedione to oestrone may account for most of the oestrogen production in post-menopausal women there is evidence to suggest that this may not be the case. While aminoglutethimide will cause a near complete inhibition of the peripheral conversion of androstenedione into oestrone, the finding of sustained plasma oestrone and oestradiol levels at about 50% of their control values (Dowsett et al., 1985; H0ffken et al., 1986; Santen et al., 1982b; Vermeulen et al., 1983) would seem to suggest that alternative oestrogen production pathways exist. This is supported by isotopic tracer studies, which failed to account for total oestrogen production from androstenedione alone (Kirschner et al., 1978; Reed et al., 1986) .
The relative contribution of the different plasma oestrogens (e.g. oestrone, oestradiol, oestrone sulphate) to intracellular tumour oestradiol is not completely understood. Neither is it clear to what extent plasma oestrogens may account for intracellular oestrone and oestradiol levels which are more than 10 times their plasma level in post-menopausal women (Edery et al., 1981; Fishman et al., 1977; Millington et al., 1974; Vermeulen et al., 1986) . Isotopic labelled steroid infusions have suggested that oestrogens are concentrated inside the tumours to between 3 and 10 times the levels in plasma (McNeill et al., 1986) . A number of studies on tumour tissue in vitro have suggested that intratumoural aromatase activity may be responsible for at least some of the intracellular oestrogen (Bezwoda et al., 1987; Lipton et al., 1987) , and one in vivo study has indicated that for some tumours such synthetic activity may be responsible for the majority of the intratumoral oestrogen (James et al., 1988) . The possibility that oestrogens may be produced in the fat or stroma surrounding breast tumours has recently been raised (O'Neill et al., 1988) . The effect of aromatase inhibitors on this local production of oestrogens could be an important part of their mechanism of action.
The steroid derivative 4-hydroxyandrostenedione is a potent irreversible aromatase inhibitor (Brodie et al., 1981) . There is no evidence so far to suggest that this drug inhibits other enzymes significantly and it is as effective as aminoglutethimide in suppressing plasma oestradiol and oestrone (Dowsett et al., 1989) . Clinical trials indicate that the drug is effective at inducing clinical remission by both the intramuscular (Goss et al., 1986) , and oral routes (Cunningham et al., 1987) . The response rate appears to be similar to aminoglutethimide treatment, but this should be confirmed in further randomised studies.
An imidazole derivative, CGS 16949A, is currently undergoing phase II trials. In vitro and in vivo investigations have shown this drug to be a highly potent aromatase inhibitor (Schieweck et al., 1988; Steele et al., 1988) . Plasma oestrone and oestradiol levels are suppressed to a similar extent to these with aminoglutethimide (Santen, 1988; Dowsett et al., 1988; Klepp et al., 1989) . However, oestrone sulphate is not equally suppressed (Klepp et al., 1989) , possibly because CGS 16949A, unlike aminoglutethimide does not increase the metabolic degradation of this steroid. Unfortunately, CGS 16949A does not seem to be a totally specific aromatase inhibitor, as it has been found to suppress aldosterone levels in patients (Dowsett et al., 1988) .
Pyridoglutethimide, a derivative of aminoglutethimide, will inhibit aromatase in vitro, but unlike aminoglutethimide has no effect on the adrenal 20, 22-desmolase (Foster et al., 1985) . This drug is now undergoing phase I trials including investigations to evaluate its effect on plasma oestrogen levels and the secretion of adrenal steroid hormones.
With an increasing number of new aromatase inhibitors discovered in the laboratory, the importance of selecting the right drug for clinical use will become mandatory. Currently, many patients receive tamoxifen for adjuvant treatment, and aromatase inhibition might become first-line endocrine treatment for advanced disease. In vitro drug potency may be a poor indicator of clinical efficacy and therapeutic ratio. The important question is, of course, whether side effects occur when a drug is administered at the dose necessary to achieve maximal reduction in oestrogen levels.
Any difference in enzyme specificity between different drugs should be carefully considered. The need for glucocorticoid (and sometimes mineralocorticoid) substitution in patients on aminoglutethimide is a disadvantage; however, in skilled hands the adrenal effects of aminoglutethimide treatment do not normally cause significant problems.
More inconvenient for many patients on aminoglutethimide treatment are the subjective side-effects related to the CNS (drowsiness, lethargy, etc.) as well as the frequent occurrence of skin rash (L0nning & Kvinnsland, 1988) . While in most patients such side-effects will subside during the first few weeks on treatment, in some patients they will cause long-term discomfort. The danger of serious blood dyscrasias (in about 1% of patients on aminoglutethimide treatment) is a potential hazard caused by treatment with this drug.
The majority of work on 4-hydroxyandrostenedione has been on the intramuscular route of administration, and although this is undergoing a phase III trial against tamoxifen some clinicians will consider the schedule of injections at 2-weekly intervals disadvantageous. Further work on oral administration is needed.
While patient compliance to different aromatase inhibitors will be an important matter, two other important and possibly related points need to be assessed: do the different aromatase inhibitors act by identical mechanisms of action, and do they cause a similar response rate?
It is clear that testololactone and aminoglutethimide, despite a 90% and 95-98% inhibition of peripheral aromatase respectively, do not have a similar effect on breast cancer growth. It is difficult to believe that such a display is caus&d solely by the marginal difference in their ability to inhibit the conversion of circulating androstenedione into oestrone. Alternatively, it is possible that this difference may be due to a different potency of the two drugs in their action on aromatase within the tumour (or surrounding tissue), or to alterations in plasma oestrone sulphate metabolism caused by aminoglutethimide treatment. Careful studies of the effects of different aromatase inhibitors on plasma oestrogen as well as local steriod disposition are needed to provide a rationale for further development of these exciting drugs in the treatment of breast cancer. 
